title: Effect of trypsin-chymotrypsin (Chymoral Forte D.S.) preparation on the modulation of cytokine levels in burn patients.
abstract: The present study was carried out in burn patients administered with Trypsin-Chymotrypsin (Chymoral Forte D.S.) preparation to observe if the acute-phase protein levels in the serum are modulated through the synthesis of IL-1beta and IL-6 and if the severity of the inflammatory phase could be regulated. The effects of Trypsin-Chymotrypsin preparation on the modulation of cytokine levels particularly, IL-6 and IL-1beta were analyzed in serum samples of 15 burn patients and compared with untreated controls. Significant differences in cytokine levels (P<0.05) were observed in untreated burn patients and Trypsin-Chymotrypsin preparation treated patients. There were significant variations in serum IL-6 and IL-1beta on the day of admission and post burn day 10 in treated as well as untreated burn patients. Patients with a higher percentage of total body surface area and sepsis showed a significant increase in IL-1beta and IL-6 in the serum. An increase in serum levels of both cytokines was observed on post burn day 1 and a significant decrease was observed in Trypsin-Chymotrypsin preparation treated patients on days 7 and 10. The possible role of the inflammatory cytokines in the pathophysiology of burns is discussed.
authors.affiliation: Department of Biotechnology, Central Leather Research Institute, Adayar 600 020, Chennai, India
authors.forename: T
authors.initials: T
authors.lastname: RaviKumar
authors.forename: M
authors.initials: M
authors.lastname: Ramakrishnan
authors.forename: V
authors.initials: V
authors.lastname: Jayaraman
authors.forename: M
authors.initials: M
authors.lastname: Babu
mesh_terms: D000293:Adolescent; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002056:Burns / Q000097:blood / Q000188:drug therapy*; D016022:Case-Control Studies; D002918:Chymotrypsin / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007375:Interleukin-1 / Q000097:blood*; D015850:Interleukin-6 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014357:Trypsin / Q000627:therapeutic use*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D004338:Drug Combinations; D007375:Interleukin-1; D015850:Interleukin-6; C007059:chymotrypsin, trypsin drug combination; D002918:Chymotrypsin; D014357:Trypsin